Clinical Trial Update: Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and immunogenicity of two doses of an H5N1 influenza vaccine in healthy adults. Results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Influenza Virus Subtype H5n1

Drugs mentioned

• H5N1 influenza vaccine (influenza vaccine H5N1)

Snippet

Sponsor: Novartis Vaccines | Conditions: Pandemic H5N1 Influenza | Phase 2 | Status: COMPLETED | Results posted: 2015-02-03